With a New Drug Approval currently under review by the Food & Drug Administration for mifamurtide, manufacturer IDM Pharma Inc. has announced the availability of the drug through a compassionate access study. The therapy, also known as L-MTP-PE, is an orphan drug used in combination with other drugs for the treatment of osteosarcoma. In order to be eligible to participate, patients must have a confirmed diagnosis of high-grade osteosarcoma with relapsed or recurrent disease, either locally or metastatic, with resectable or not completely resectable disease, or who are unable to complete recommended chemotherapy due to toxicity. The study will be conducted initially at M.D. Anderson and Memorial Sloan Kettering Cancer Center in New York. More information can be found at www.clinicaltrials.gov.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.